BCL2L1 and hematologic disorder: In this regard, ABT-199, S63845 (MCL-1 inhibitor), and A-1331852 (BCL-xL inhibitor) have been described to affect ∆ψm in hematological malignancies accompanied by swollen mitochondria, rupture of the mitochondrial outer membrane as well as loss of cristae structure (Henz et al. 2019).